Genprex to spin out diabetes gene therapy program into new subsidiary GPX-002

Genprex, Inc.

Intends to transfer diabetes clinical development and gene therapy assets to wholly-owned NewCo.
NewCo will focus on GPX-002 for Type 1 and Type 2 diabetes; Genprex retains oncology programs.
Spin-out expected by end of 2024, subject to financing, conditions, and board approval.
Reorganization follows recent refocus on oncology lead Reqorsa Gene Therapy for expedited regulatory submission.
Company continues to evaluate strategic alternatives to enhance stockholder value.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.